One Name On 239 Of 244 Families
Hejian holds 244 patent families: 149 granted and 95 published and pending. Filing began in 2005, with the most recent published filing dated 2025-09-25. The families appear in 3 patent offices: United States, China and Canada.Patent figures from Google Patents Public Data, reviewed 2026-09-17. Funding: $164.5M Seed, 2022-06-01. Assignee matching for this company is ambiguous and the figures need manual confirmation.
A $164.5M seed round arrived in 2022, seventeen years after the first filing. The portfolio behind it runs from medicinal preparations to wireless networks to needle roller bearings, and almost every family carries the same inventor name. What kind of record is that?
The Money Came Seventeen Years Late
The pulse is dated June 2022: $164.5M, announced as a seed round. Seed rounds are usually the first money into a company that has just started making things. This one landed on a filing record that began on 16 March 2005 and had already produced well over two hundred patent families by the time the cheque cleared.
That gap is the first thing worth holding on to. Whatever the capital was for, it was not funding the beginning of the invention work. The invention work had been running for seventeen years, through offices in China, the United States and Canada, and it had already passed its busiest year. The money arrived late to a story in progress.
Seed money on a seventeen-year-old filing record is not seed money in the usual sense.
Two Hundred Forty-Four Ticks, Mostly Solid
Every family in the record is one tick here. There are 244 of them. The solid amber ones, 149 in total, are granted. The thin ones, 95, are published and still pending. Sixty-one percent granted is a working record rather than a hopeful one: most of what was filed has survived examination somewhere.
The arc also carries the shape of the effort. Three families in 2005, five in 2006, then a slow climb through the low teens before 2016 brought 26 in a single year. The most recent published filing is dated 25 September 2025, which means the record is still open. Twenty years of continuous filing, no long silence anywhere in it.
Medicine, Then Wireless, Then Bearings
The bands do not stack the way a single-product company's would. The largest is A61K, medicinal preparations, on 13 families. A61P follows on 12. Then H04W, wireless networks, on 7, and H04L, digital communication, on 7. C07K, peptides and antibodies, holds 6. H04N holds 5.
Read the recent titles against those bands and the spread gets wider still. A thrust double-row needle roller bearing. A surrounding capture space position sharing system. A split type intelligent AR service device for police. A cross-platform multidirectional circulation consumption integration system. Medicinal chemistry and radio protocols and rolling-element bearings do not normally share a filing programme. Here they share the same arc.
Two Hundred Seventy Names, One Constant
There are 271 inventor names in this portfolio, which looks like a large research organisation. The highlighted dot changes that reading. HE JIAN is named on 239 of the 244 families. The next most frequent names are TAI JIANXIANG on 9 and LIU XIAOWEI on 8. Everyone else appears once or twice.
So the breadth in the previous stage is not a division of labour. It is one person's range, recorded over twenty years, with collaborators joining for single projects and moving on. The 271 names are the collaborators. The 239 are the thread. That is why medicinal preparations and needle roller bearings can sit in the same file without contradiction.
The breadth is not a company's breadth. It is one inventor's.
The Citations Point One Direction Only
Five organisations account for the citations back into this portfolio. MERCK SHARP & DOHME LLC cites it 28 times. C3 JIAN INC, 26. PFIZER, 18. UNIV CORNELL, 18. UNIV CALIFORNIA, 16. The lines all connect to the same region of the arc, and it is not the wireless region or the bearing region.
The A61K, A61P and C07K families amount to 31 of 244. They are a minority of the filings and effectively all of the outside attention. The CPC groups those families sit in are also worked heavily by others: REGENERON PHARMA filed 362 families there in the last five years, UNIV CALIFORNIA 311, GENENTECH INC 259, JANSSEN BIOTECH INC 242, HOFFMANN LA ROCHE 230, UNIV PENNSYLVANIA 226.
Where The Record Is Actually Load-Bearing
The plain version, now that the file has been laid out: this is one inventor's twenty-year notebook, filed properly and granted at 61 percent, and the part of it that others have picked up is the smallest part. Thirty-one families in medicinal preparations, therapeutic activity and peptides draw every citation on the chart. The other two hundred and thirteen draw none of them.
That is not a weakness in the wider filings. It is a statement about where the value has been recognised so far. Filing volume fell to 6 families in 2023 and 1 in 2024 before returning to 6 in 2025, so the programme has narrowed. The open question is whether the narrowing points at the cited third or away from it.
Is a single-inventor portfolio a durable position?
Three things about this record can be checked independently. Any one of them on its own is easy to misread, because a long filing history, a high grant rate and outside citations each have innocent explanations.
A claim without a record
Nothing in the file supports duration, survival or outside reading. Treat the portfolio as unproven.
Where The Record Is Actually Load-Bearing
Do the families filed after the 2022 round sit in A61K, A61P and C07K, or in the wireless and mechanical groups?
Does HE JIAN remain the sole constant name on filings made since 2023, or do new recurring co-inventors appear?
Do the 95 pending families grant at the same 61 percent rate as the earlier cohort, and in which offices?
Do citations from MERCK SHARP & DOHME LLC, PFIZER and the university filers continue to land only on the peptide and medicinal families?
Following those four would tell you whether this record is consolidating around the third of it that others have already read, or continuing to spread.
Common questions
How many patents does Hejian have?
Hejian holds 244 patent families as reviewed in 2026-09: 149 granted and 95 published and pending.
How many of Hejian's patents are granted?
149 of the 244 families are granted, or 61 percent. The remaining 95 are published and still under examination.
What technology do Hejian's patents cover?
Hejian's claims cluster in medicinal preparations (A61K), therapeutic activity (A61P) and wireless networks (H04W). Recent filing titles include "Thrust double-row needle roller bearing" and "Surrounding capture space position sharing system and method".
Where has Hejian filed patents?
Hejian's families appear in 3 patent offices: United States, China and Canada.
Which companies file patents in the same areas as Hejian?
The same CPC groups drew REGENERON PHARMA, UNIV CALIFORNIA, GENENTECH INC and JANSSEN BIOTECH INC over the last five years. Shared classification indicates a common technology field rather than direct competition.
Who cites Hejian's patents?
Patent records from MERCK SHARP & DOHME LLC, C3 JIAN INC, PFIZER and UNIV CORNELL cite Hejian's filings. A citation indicates a reference to the work, not evidence of commercial use.
Who invented Hejian's patents?
271 inventors are named across the portfolio. The most frequently named is HE JIAN. Inventor names do not establish ownership, which is determined by assignment records.
GET IN TOUCH NOW!
OR SCHEDULE A MEETING
